earnings
confidence high
sentiment positive
materiality 0.80
Vertex Q3 rev $3.08B (+11% YoY), FY guidance refined; povetacicept IgAN BLA on track
VERTEX PHARMACEUTICALS INC / MA
2025-Q3 EPS
reported $10.68
vs consensus $4.65
▲ beat
(+129.4%)
- Q3 total revenue $3.08B (+11% vs Q3 2024); GAAP net income $1.1B, non-GAAP $1.2B.
- FY2025 revenue guidance raised to $11.9-12.0B; non-GAAP OpEx guidance $5.0-5.1B; tax rate lowered to 17-18%.
- Povetacicept Phase 3 IgAN enrollment complete; first BLA module submission to FDA by end of 2025.
- JOURNAVX: >300K prescriptions since March; CASGEVY: 165 cell collections, 39 infusions globally.
- Zimislecel T1D trial enrollment complete; dosing temporarily postponed pending manufacturing analysis.